Deep sequencing targeting DNA damage repair pathways identifies ARID1A as a prognostic biomarker for gliomas and its mutation alters SWI/SNF stability increasing the malignant phenotype of GBM and mediating chemoresistance. Here, ARID1A is linked to central nervous system cancer.